Ping-Ching Hsu
Concepts (526)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Helicobacter pylori | 11 | 2014 | 66 | 2.230 |
Why?
| Helicobacter Infections | 9 | 2014 | 64 | 2.130 |
Why?
| Carcinoma, Non-Small-Cell Lung | 6 | 2024 | 154 | 1.370 |
Why?
| Hepatitis B, Chronic | 7 | 2014 | 16 | 1.340 |
Why?
| Smoking | 5 | 2016 | 511 | 1.330 |
Why?
| Tumor Necrosis Factor-alpha | 6 | 2014 | 388 | 1.260 |
Why?
| Hepatitis B virus | 5 | 2014 | 27 | 1.150 |
Why?
| Menthol | 2 | 2016 | 17 | 1.100 |
Why?
| Lung Neoplasms | 6 | 2024 | 606 | 1.040 |
Why?
| Metabolome | 2 | 2016 | 89 | 0.930 |
Why?
| Nicotine | 2 | 2016 | 187 | 0.900 |
Why?
| Carcinoma, Hepatocellular | 8 | 2014 | 191 | 0.870 |
Why?
| Liver Neoplasms | 9 | 2014 | 326 | 0.850 |
Why?
| Middle Aged | 47 | 2024 | 12069 | 0.810 |
Why?
| Spermatozoa | 3 | 2007 | 23 | 0.780 |
Why?
| Apoptosis | 6 | 2014 | 1101 | 0.740 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 989 | 0.710 |
Why?
| Peptic Ulcer | 3 | 2010 | 14 | 0.710 |
Why?
| Induction Chemotherapy | 1 | 2019 | 60 | 0.670 |
Why?
| Aged | 36 | 2024 | 9310 | 0.670 |
Why?
| TNF-Related Apoptosis-Inducing Ligand | 5 | 2012 | 20 | 0.660 |
Why?
| Membrane Glycoproteins | 3 | 2005 | 240 | 0.650 |
Why?
| Lymphocyte Activation | 3 | 2010 | 172 | 0.650 |
Why?
| Male | 57 | 2024 | 25241 | 0.650 |
Why?
| Metabolomics | 2 | 2016 | 126 | 0.640 |
Why?
| Cisplatin | 3 | 2019 | 278 | 0.630 |
Why?
| Proton Pump Inhibitors | 2 | 2010 | 84 | 0.600 |
Why?
| Apoptosis Regulatory Proteins | 5 | 2010 | 86 | 0.600 |
Why?
| Female | 51 | 2024 | 26472 | 0.590 |
Why?
| Hepatitis B Core Antigens | 2 | 2014 | 7 | 0.580 |
Why?
| Polychlorinated Biphenyls | 3 | 2007 | 25 | 0.570 |
Why?
| Glucuronates | 1 | 2016 | 23 | 0.560 |
Why?
| Testis | 2 | 2007 | 69 | 0.540 |
Why?
| Humans | 69 | 2024 | 49974 | 0.530 |
Why?
| Genetic Predisposition to Disease | 3 | 2015 | 510 | 0.530 |
Why?
| Up-Regulation | 7 | 2014 | 452 | 0.530 |
Why?
| Gastritis | 2 | 2007 | 32 | 0.530 |
Why?
| Adult | 34 | 2024 | 13236 | 0.520 |
Why?
| Gastrointestinal Hemorrhage | 7 | 2014 | 78 | 0.520 |
Why?
| Programmed Cell Death 1 Receptor | 2 | 2012 | 38 | 0.500 |
Why?
| Endoscopy, Digestive System | 2 | 2012 | 50 | 0.470 |
Why?
| Anti-Bacterial Agents | 6 | 2014 | 744 | 0.460 |
Why?
| Immunity, Innate | 1 | 2014 | 104 | 0.450 |
Why?
| Disease Models, Animal | 3 | 2014 | 1455 | 0.450 |
Why?
| Esophageal and Gastric Varices | 6 | 2012 | 13 | 0.440 |
Why?
| Lymphoma, B-Cell, Marginal Zone | 2 | 2010 | 23 | 0.440 |
Why?
| Cholecystolithiasis | 1 | 2012 | 1 | 0.430 |
Why?
| Bile Duct Diseases | 1 | 2012 | 11 | 0.430 |
Why?
| Choledocholithiasis | 1 | 2012 | 12 | 0.430 |
Why?
| Taiwan | 7 | 2014 | 23 | 0.420 |
Why?
| Aged, 80 and over | 13 | 2024 | 3129 | 0.420 |
Why?
| Antigens, Bacterial | 2 | 2010 | 54 | 0.420 |
Why?
| Duodenal Ulcer | 3 | 2009 | 12 | 0.410 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2012 | 116 | 0.390 |
Why?
| Galectin 3 | 1 | 2011 | 14 | 0.380 |
Why?
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2010 | 3 | 0.380 |
Why?
| Membrane Microdomains | 1 | 2010 | 12 | 0.380 |
Why?
| Tobacco Products | 1 | 2013 | 110 | 0.380 |
Why?
| NF-kappa B | 3 | 2010 | 314 | 0.370 |
Why?
| T-Lymphocytes | 2 | 2010 | 338 | 0.370 |
Why?
| Arthritis, Rheumatoid | 1 | 2011 | 105 | 0.360 |
Why?
| Ticlopidine | 1 | 2010 | 55 | 0.360 |
Why?
| Gastric Juice | 1 | 2010 | 6 | 0.360 |
Why?
| Chemotaxis, Leukocyte | 2 | 2007 | 13 | 0.350 |
Why?
| Macrophage Inflammatory Proteins | 2 | 2007 | 5 | 0.350 |
Why?
| Endoscopy, Gastrointestinal | 6 | 2012 | 73 | 0.350 |
Why?
| alpha 1-Antitrypsin | 1 | 2010 | 14 | 0.350 |
Why?
| Stomach Neoplasms | 2 | 2010 | 174 | 0.340 |
Why?
| Esophagitis | 1 | 2009 | 9 | 0.340 |
Why?
| Bacterial Proteins | 3 | 2010 | 376 | 0.340 |
Why?
| Antigens, CD | 1 | 2010 | 219 | 0.330 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2010 | 172 | 0.330 |
Why?
| Serologic Tests | 1 | 2008 | 26 | 0.330 |
Why?
| Neoplasm Staging | 5 | 2021 | 740 | 0.330 |
Why?
| Breath Tests | 1 | 2008 | 39 | 0.330 |
Why?
| Anti-Ulcer Agents | 2 | 2005 | 21 | 0.320 |
Why?
| Sulfoxides | 2 | 2005 | 19 | 0.320 |
Why?
| Signal Transduction | 7 | 2014 | 1618 | 0.320 |
Why?
| Urea | 1 | 2008 | 77 | 0.320 |
Why?
| Antibodies, Antinuclear | 2 | 2007 | 14 | 0.320 |
Why?
| Chemokines, CC | 2 | 2007 | 7 | 0.310 |
Why?
| Benzimidazoles | 2 | 2005 | 48 | 0.310 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2011 | 485 | 0.310 |
Why?
| Atherosclerosis | 1 | 2010 | 214 | 0.310 |
Why?
| Gastric Mucosa | 2 | 2007 | 47 | 0.310 |
Why?
| HLA-DR2 Antigen | 1 | 2007 | 1 | 0.310 |
Why?
| Prospective Studies | 9 | 2019 | 2364 | 0.300 |
Why?
| Cell Proliferation | 2 | 2014 | 1007 | 0.300 |
Why?
| Amoxicillin | 4 | 2014 | 21 | 0.300 |
Why?
| Receptors, Chemokine | 1 | 2007 | 12 | 0.300 |
Why?
| Liver | 7 | 2014 | 1115 | 0.300 |
Why?
| Enzyme Activation | 5 | 2010 | 276 | 0.290 |
Why?
| Liver Cirrhosis | 6 | 2012 | 218 | 0.290 |
Why?
| Pseudarthrosis | 1 | 2006 | 1 | 0.280 |
Why?
| Arthritis, Psoriatic | 1 | 2006 | 9 | 0.280 |
Why?
| Hepatitis C, Chronic | 1 | 2007 | 83 | 0.280 |
Why?
| Mass Screening | 1 | 2010 | 353 | 0.280 |
Why?
| Lupus Erythematosus, Systemic | 2 | 2004 | 70 | 0.280 |
Why?
| Flame Retardants | 1 | 2006 | 1 | 0.280 |
Why?
| Polybrominated Biphenyls | 1 | 2006 | 1 | 0.280 |
Why?
| Phenyl Ethers | 1 | 2006 | 5 | 0.280 |
Why?
| Epididymis | 1 | 2006 | 8 | 0.280 |
Why?
| Monocytes | 4 | 2014 | 131 | 0.270 |
Why?
| Spinal Fractures | 1 | 2006 | 38 | 0.270 |
Why?
| Peroxidase | 1 | 2005 | 15 | 0.260 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2010 | 129 | 0.260 |
Why?
| Viral Core Proteins | 1 | 2005 | 6 | 0.250 |
Why?
| Gallstones | 4 | 2009 | 13 | 0.250 |
Why?
| DNA | 3 | 2015 | 541 | 0.250 |
Why?
| Naphthoquinones | 1 | 2004 | 10 | 0.250 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2007 | 186 | 0.250 |
Why?
| Mitochondria, Liver | 1 | 2005 | 70 | 0.240 |
Why?
| Hepacivirus | 1 | 2005 | 104 | 0.230 |
Why?
| Immunologic Factors | 1 | 2005 | 114 | 0.230 |
Why?
| Antiviral Agents | 3 | 2014 | 173 | 0.230 |
Why?
| Cachexia | 1 | 2003 | 25 | 0.230 |
Why?
| Young Adult | 5 | 2019 | 3958 | 0.220 |
Why?
| Triiodothyronine | 1 | 2003 | 29 | 0.220 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 121 | 0.220 |
Why?
| Enzyme Inhibitors | 1 | 2005 | 391 | 0.220 |
Why?
| Sex Factors | 4 | 2016 | 691 | 0.220 |
Why?
| Reactive Oxygen Species | 4 | 2007 | 408 | 0.220 |
Why?
| Carrier Proteins | 1 | 2005 | 304 | 0.220 |
Why?
| Follow-Up Studies | 8 | 2020 | 2182 | 0.210 |
Why?
| Antibodies, Monoclonal | 2 | 2020 | 459 | 0.210 |
Why?
| Risk Assessment | 5 | 2016 | 1259 | 0.210 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2004 | 164 | 0.210 |
Why?
| Lipopolysaccharides | 5 | 2008 | 192 | 0.210 |
Why?
| 2-Pyridinylmethylsulfinylbenzimidazoles | 3 | 2014 | 19 | 0.200 |
Why?
| Metronidazole | 2 | 2012 | 29 | 0.200 |
Why?
| Clarithromycin | 3 | 2014 | 38 | 0.200 |
Why?
| Organometallic Compounds | 2 | 2012 | 44 | 0.200 |
Why?
| Animals | 12 | 2014 | 13187 | 0.200 |
Why?
| Cells, Cultured | 6 | 2015 | 1573 | 0.200 |
Why?
| Treatment Outcome | 12 | 2021 | 5141 | 0.200 |
Why?
| Age Factors | 4 | 2016 | 1087 | 0.200 |
Why?
| Colorectal Neoplasms | 1 | 2004 | 236 | 0.190 |
Why?
| Sigmoidoscopy | 2 | 2014 | 10 | 0.190 |
Why?
| Cross-Sectional Studies | 3 | 2016 | 1557 | 0.190 |
Why?
| Mice | 8 | 2014 | 5739 | 0.190 |
Why?
| Virus Replication | 2 | 2014 | 140 | 0.190 |
Why?
| Reproducibility of Results | 2 | 2016 | 1193 | 0.190 |
Why?
| Drug Therapy, Combination | 7 | 2013 | 377 | 0.180 |
Why?
| Cohort Studies | 2 | 2019 | 1422 | 0.180 |
Why?
| Adenine | 2 | 2013 | 32 | 0.180 |
Why?
| Interferon-gamma | 3 | 2012 | 177 | 0.170 |
Why?
| Sulfones | 1 | 2019 | 24 | 0.170 |
Why?
| Chemoradiotherapy | 1 | 2020 | 40 | 0.170 |
Why?
| Salvage Therapy | 1 | 2020 | 139 | 0.170 |
Why?
| Recurrence | 6 | 2012 | 652 | 0.170 |
Why?
| Oncogene Proteins, Fusion | 1 | 2019 | 58 | 0.170 |
Why?
| Prognosis | 6 | 2021 | 1942 | 0.170 |
Why?
| Mutation | 2 | 2024 | 1294 | 0.170 |
Why?
| Multivariate Analysis | 4 | 2016 | 577 | 0.160 |
Why?
| Sphincterotomy, Endoscopic | 3 | 2009 | 15 | 0.160 |
Why?
| Adolescent | 5 | 2016 | 6356 | 0.160 |
Why?
| Pyrimidines | 1 | 2019 | 192 | 0.160 |
Why?
| Administration, Oral | 1 | 2019 | 426 | 0.150 |
Why?
| Platelet Aggregation | 2 | 2010 | 71 | 0.150 |
Why?
| Somatostatin | 2 | 2008 | 30 | 0.150 |
Why?
| Pancreatitis | 2 | 2008 | 57 | 0.150 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 595 | 0.140 |
Why?
| Carcinoma, Squamous Cell | 1 | 2020 | 318 | 0.140 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2010 | 155 | 0.140 |
Why?
| Sensitivity and Specificity | 2 | 2010 | 861 | 0.140 |
Why?
| Nadolol | 2 | 2008 | 3 | 0.140 |
Why?
| Risk Factors | 5 | 2014 | 3613 | 0.140 |
Why?
| Caspase 9 | 2 | 2007 | 15 | 0.140 |
Why?
| Dose-Response Relationship, Drug | 5 | 2007 | 1376 | 0.130 |
Why?
| Alcohol Drinking | 2 | 2009 | 224 | 0.130 |
Why?
| Caspase 3 | 2 | 2007 | 97 | 0.130 |
Why?
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 411 | 0.130 |
Why?
| Severity of Illness Index | 5 | 2012 | 945 | 0.130 |
Why?
| Animals, Newborn | 2 | 2007 | 367 | 0.130 |
Why?
| Injections, Intraperitoneal | 2 | 2007 | 54 | 0.130 |
Why?
| Cell Line, Tumor | 3 | 2010 | 1403 | 0.130 |
Why?
| Rats, Sprague-Dawley | 4 | 2014 | 1597 | 0.130 |
Why?
| Membrane Potentials | 2 | 2006 | 117 | 0.130 |
Why?
| Sperm Count | 2 | 2006 | 10 | 0.130 |
Why?
| Sperm Motility | 2 | 2006 | 11 | 0.120 |
Why?
| Adenosine Diphosphate | 2 | 2004 | 21 | 0.120 |
Why?
| P-Selectin | 2 | 2004 | 32 | 0.120 |
Why?
| Guanine | 3 | 2014 | 40 | 0.120 |
Why?
| Leukocytes | 2 | 2004 | 66 | 0.120 |
Why?
| Caspases | 2 | 2005 | 104 | 0.120 |
Why?
| Toll-Like Receptor 9 | 1 | 2014 | 10 | 0.120 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2007 | 202 | 0.120 |
Why?
| Cyclooxygenase 2 Inhibitors | 1 | 2014 | 19 | 0.120 |
Why?
| Intestinal Polyps | 1 | 2014 | 7 | 0.120 |
Why?
| PTEN Phosphohydrolase | 1 | 2014 | 55 | 0.120 |
Why?
| Thymidine | 1 | 2013 | 18 | 0.110 |
Why?
| Aryl Hydrocarbon Hydroxylases | 2 | 2011 | 74 | 0.110 |
Why?
| Organophosphonates | 1 | 2013 | 7 | 0.110 |
Why?
| Thromboembolism | 1 | 2014 | 54 | 0.110 |
Why?
| Mice, Inbred C57BL | 4 | 2013 | 1816 | 0.110 |
Why?
| Immunocompetence | 1 | 2013 | 18 | 0.110 |
Why?
| Hysterectomy | 1 | 2014 | 88 | 0.110 |
Why?
| Dobutamine | 2 | 2003 | 16 | 0.110 |
Why?
| Adrenergic beta-Agonists | 2 | 2003 | 39 | 0.110 |
Why?
| Toll-Like Receptor 3 | 1 | 2013 | 9 | 0.110 |
Why?
| Interferons | 1 | 2013 | 38 | 0.110 |
Why?
| Chemokine CCL2 | 2 | 2003 | 70 | 0.110 |
Why?
| Area Under Curve | 2 | 2012 | 182 | 0.110 |
Why?
| Gene Frequency | 2 | 2011 | 94 | 0.110 |
Why?
| Secondary Prevention | 2 | 2010 | 78 | 0.110 |
Why?
| Cholangiopancreatography, Endoscopic Retrograde | 3 | 2009 | 88 | 0.110 |
Why?
| Cyclooxygenase 2 | 2 | 2014 | 45 | 0.110 |
Why?
| Warfarin | 1 | 2014 | 86 | 0.110 |
Why?
| Pyrazoles | 1 | 2014 | 113 | 0.110 |
Why?
| Genotype | 2 | 2013 | 537 | 0.110 |
Why?
| ROC Curve | 2 | 2012 | 232 | 0.110 |
Why?
| Interleukin-6 | 2 | 2012 | 264 | 0.110 |
Why?
| Sulfonamides | 1 | 2014 | 129 | 0.110 |
Why?
| Protein Transport | 2 | 2010 | 180 | 0.110 |
Why?
| Ofloxacin | 1 | 2012 | 7 | 0.110 |
Why?
| Cell Line | 5 | 2012 | 1000 | 0.110 |
Why?
| Rats | 4 | 2014 | 3305 | 0.110 |
Why?
| Quality Control | 1 | 2013 | 94 | 0.110 |
Why?
| Observer Variation | 1 | 2013 | 130 | 0.110 |
Why?
| Cholecystectomy | 1 | 2012 | 29 | 0.110 |
Why?
| TNF Receptor-Associated Factor 6 | 1 | 2012 | 8 | 0.100 |
Why?
| Flow Cytometry | 4 | 2014 | 476 | 0.100 |
Why?
| Hepatitis B | 2 | 2010 | 22 | 0.100 |
Why?
| Cesarean Section | 1 | 2014 | 187 | 0.100 |
Why?
| Elasticity Imaging Techniques | 1 | 2012 | 26 | 0.100 |
Why?
| Blood Platelets | 2 | 2004 | 245 | 0.100 |
Why?
| Interleukins | 1 | 2012 | 32 | 0.100 |
Why?
| Mitochondria | 2 | 2006 | 402 | 0.100 |
Why?
| Pregnancy | 3 | 2014 | 2607 | 0.100 |
Why?
| Retrospective Studies | 4 | 2021 | 6108 | 0.100 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 244 | 0.100 |
Why?
| Mice, Inbred BALB C | 1 | 2012 | 304 | 0.100 |
Why?
| Gene Expression Regulation | 4 | 2015 | 976 | 0.100 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2013 | 349 | 0.100 |
Why?
| Spleen | 1 | 2012 | 172 | 0.100 |
Why?
| Oligonucleotide Probes | 1 | 2011 | 20 | 0.100 |
Why?
| Tandem Mass Spectrometry | 1 | 2013 | 236 | 0.100 |
Why?
| Tetracycline | 1 | 2011 | 20 | 0.100 |
Why?
| Anticoagulants | 1 | 2014 | 250 | 0.100 |
Why?
| Nucleic Acid Hybridization | 1 | 2011 | 54 | 0.100 |
Why?
| Polymorphism, Restriction Fragment Length | 1 | 2011 | 66 | 0.100 |
Why?
| Immunohistochemistry | 2 | 2013 | 973 | 0.100 |
Why?
| Feasibility Studies | 1 | 2013 | 375 | 0.100 |
Why?
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2010 | 3 | 0.100 |
Why?
| Jurkat Cells | 1 | 2010 | 29 | 0.090 |
Why?
| Platelet Function Tests | 1 | 2010 | 17 | 0.090 |
Why?
| Polymorphism, Genetic | 2 | 2011 | 181 | 0.090 |
Why?
| Gene Expression Profiling | 1 | 2015 | 1032 | 0.090 |
Why?
| Drug Administration Schedule | 5 | 2013 | 376 | 0.090 |
Why?
| Organ Size | 2 | 2012 | 226 | 0.090 |
Why?
| Disease Progression | 3 | 2014 | 825 | 0.090 |
Why?
| Drug Interactions | 1 | 2010 | 206 | 0.090 |
Why?
| bcl-X Protein | 1 | 2010 | 50 | 0.090 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2010 | 78 | 0.090 |
Why?
| Lymphoma, B-Cell | 1 | 2010 | 63 | 0.090 |
Why?
| Areca | 1 | 2009 | 2 | 0.090 |
Why?
| Gallbladder Neoplasms | 1 | 2009 | 5 | 0.090 |
Why?
| Logistic Models | 2 | 2009 | 888 | 0.080 |
Why?
| Tumor Cells, Cultured | 2 | 2014 | 465 | 0.080 |
Why?
| B-Lymphocytes | 1 | 2010 | 170 | 0.080 |
Why?
| Cell Differentiation | 1 | 2012 | 651 | 0.080 |
Why?
| bcl-2-Associated X Protein | 2 | 2007 | 56 | 0.080 |
Why?
| Body Mass Index | 2 | 2009 | 652 | 0.080 |
Why?
| Catechols | 1 | 2008 | 7 | 0.080 |
Why?
| Bilirubin | 2 | 2007 | 40 | 0.080 |
Why?
| Capsules | 1 | 2008 | 30 | 0.080 |
Why?
| Osteoclasts | 1 | 2012 | 425 | 0.080 |
Why?
| Albumins | 1 | 2009 | 31 | 0.080 |
Why?
| DNA, Viral | 3 | 2014 | 133 | 0.080 |
Why?
| Endotoxins | 1 | 2009 | 34 | 0.080 |
Why?
| Antibodies, Bacterial | 1 | 2008 | 28 | 0.080 |
Why?
| Peritonitis | 1 | 2009 | 27 | 0.080 |
Why?
| Carbon Isotopes | 1 | 2008 | 68 | 0.080 |
Why?
| Chi-Square Distribution | 1 | 2009 | 280 | 0.080 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2008 | 66 | 0.080 |
Why?
| Isosorbide Dinitrate | 1 | 2008 | 1 | 0.080 |
Why?
| B-Cell Activating Factor | 1 | 2008 | 3 | 0.080 |
Why?
| Intestinal Mucosa | 2 | 2007 | 225 | 0.080 |
Why?
| Prevalence | 2 | 2009 | 944 | 0.080 |
Why?
| Digestive System Surgical Procedures | 1 | 2008 | 33 | 0.080 |
Why?
| Adenomyoma | 1 | 2008 | 2 | 0.080 |
Why?
| Jejunal Neoplasms | 1 | 2008 | 4 | 0.080 |
Why?
| Immunoglobulin G | 1 | 2008 | 186 | 0.080 |
Why?
| Dietary Fats | 1 | 2009 | 133 | 0.080 |
Why?
| Antibody Specificity | 1 | 2007 | 36 | 0.080 |
Why?
| Ligands | 2 | 2006 | 204 | 0.080 |
Why?
| p38 Mitogen-Activated Protein Kinases | 2 | 2008 | 96 | 0.080 |
Why?
| Vasodilator Agents | 1 | 2008 | 96 | 0.080 |
Why?
| Phenotype | 1 | 2010 | 729 | 0.080 |
Why?
| Adrenergic beta-Antagonists | 1 | 2008 | 102 | 0.080 |
Why?
| Chemokine CCL20 | 1 | 2007 | 1 | 0.070 |
Why?
| Receptors, CCR6 | 1 | 2007 | 3 | 0.070 |
Why?
| Receptors, CXCR3 | 1 | 2007 | 3 | 0.070 |
Why?
| Receptors, CCR5 | 1 | 2007 | 6 | 0.070 |
Why?
| Radiopharmaceuticals | 1 | 2008 | 209 | 0.070 |
Why?
| Survival Rate | 3 | 2020 | 894 | 0.070 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 181 | 0.070 |
Why?
| Immunologic Memory | 1 | 2007 | 30 | 0.070 |
Why?
| DNA Primers | 2 | 2004 | 207 | 0.070 |
Why?
| T-Lymphocyte Subsets | 1 | 2007 | 39 | 0.070 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2008 | 105 | 0.070 |
Why?
| Th1 Cells | 1 | 2007 | 52 | 0.070 |
Why?
| Models, Biological | 2 | 2008 | 727 | 0.070 |
Why?
| Interleukin-8 | 2 | 2005 | 87 | 0.070 |
Why?
| Chemotaxis | 2 | 2003 | 23 | 0.070 |
Why?
| Spondylitis, Ankylosing | 1 | 2006 | 9 | 0.070 |
Why?
| Inflammation Mediators | 1 | 2007 | 112 | 0.070 |
Why?
| Time Factors | 2 | 2010 | 2903 | 0.070 |
Why?
| Halogenated Diphenyl Ethers | 1 | 2006 | 1 | 0.070 |
Why?
| Steroid 11-beta-Hydroxylase | 1 | 2006 | 1 | 0.070 |
Why?
| RNA, Messenger | 5 | 2014 | 1105 | 0.070 |
Why?
| Hemostasis, Endoscopic | 1 | 2006 | 4 | 0.070 |
Why?
| Pilot Projects | 2 | 2005 | 699 | 0.070 |
Why?
| Ligation | 4 | 2008 | 59 | 0.070 |
Why?
| Macrophages | 1 | 2008 | 363 | 0.070 |
Why?
| Proto-Oncogene Proteins | 2 | 2008 | 149 | 0.070 |
Why?
| Gastroscopy | 1 | 2005 | 19 | 0.070 |
Why?
| Cytokines | 1 | 2009 | 612 | 0.070 |
Why?
| Ketotifen | 1 | 2005 | 2 | 0.060 |
Why?
| Leukotriene Antagonists | 1 | 2005 | 4 | 0.060 |
Why?
| Case-Control Studies | 3 | 2014 | 1131 | 0.060 |
Why?
| Histamine H1 Antagonists | 1 | 2005 | 10 | 0.060 |
Why?
| Diet | 1 | 2009 | 566 | 0.060 |
Why?
| Caspase 8 | 1 | 2005 | 12 | 0.060 |
Why?
| Fas Ligand Protein | 1 | 2005 | 17 | 0.060 |
Why?
| Quinolines | 1 | 2005 | 40 | 0.060 |
Why?
| BH3 Interacting Domain Death Agonist Protein | 1 | 2005 | 14 | 0.060 |
Why?
| Genes, Bacterial | 1 | 2005 | 64 | 0.060 |
Why?
| Chromatin | 1 | 2006 | 151 | 0.060 |
Why?
| Chemokines | 1 | 2005 | 77 | 0.060 |
Why?
| Anti-Asthmatic Agents | 1 | 2005 | 30 | 0.060 |
Why?
| Hydrolysis | 1 | 2005 | 63 | 0.060 |
Why?
| Acetates | 1 | 2005 | 49 | 0.060 |
Why?
| Kaplan-Meier Estimate | 2 | 2021 | 466 | 0.060 |
Why?
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2004 | 18 | 0.060 |
Why?
| Midazolam | 1 | 2004 | 38 | 0.060 |
Why?
| Anesthesia, Inhalation | 1 | 2004 | 12 | 0.060 |
Why?
| Cytochromes c | 1 | 2004 | 29 | 0.060 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2004 | 30 | 0.060 |
Why?
| Cholesterol | 1 | 2005 | 146 | 0.060 |
Why?
| Methyl Ethers | 1 | 2004 | 18 | 0.060 |
Why?
| Anesthetics, Intravenous | 1 | 2004 | 24 | 0.060 |
Why?
| Chronic Disease | 1 | 2007 | 567 | 0.060 |
Why?
| Acrylamides | 1 | 2024 | 6 | 0.060 |
Why?
| DNA Fragmentation | 1 | 2004 | 55 | 0.060 |
Why?
| Gene Expression | 1 | 2007 | 609 | 0.060 |
Why?
| Injections, Subcutaneous | 1 | 2024 | 54 | 0.060 |
Why?
| Receptors, Interleukin-2 | 1 | 2004 | 7 | 0.060 |
Why?
| Antibodies, Blocking | 1 | 2004 | 8 | 0.060 |
Why?
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2004 | 6 | 0.060 |
Why?
| Patient Compliance | 1 | 2005 | 230 | 0.060 |
Why?
| Immunotoxins | 1 | 2004 | 6 | 0.060 |
Why?
| Coculture Techniques | 1 | 2004 | 146 | 0.060 |
Why?
| Administration, Intravenous | 1 | 2024 | 69 | 0.060 |
Why?
| Immunoglobulin Fc Fragments | 1 | 2004 | 11 | 0.060 |
Why?
| Tranexamic Acid | 1 | 2004 | 15 | 0.060 |
Why?
| Esophagoscopy | 1 | 2004 | 27 | 0.060 |
Why?
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 36 | 0.060 |
Why?
| Interleukin-2 | 1 | 2004 | 72 | 0.060 |
Why?
| Leukocytes, Mononuclear | 2 | 2015 | 116 | 0.060 |
Why?
| Cystitis | 1 | 2004 | 17 | 0.060 |
Why?
| Body Weight | 1 | 2006 | 513 | 0.060 |
Why?
| Tumor Suppressor Proteins | 1 | 2004 | 128 | 0.060 |
Why?
| Pancreatic Pseudocyst | 1 | 2003 | 7 | 0.060 |
Why?
| Protozoan Proteins | 1 | 2004 | 31 | 0.060 |
Why?
| Jaundice, Obstructive | 1 | 2003 | 7 | 0.060 |
Why?
| Protein Processing, Post-Translational | 1 | 2005 | 171 | 0.060 |
Why?
| Cell Cycle Proteins | 1 | 2004 | 166 | 0.060 |
Why?
| Lidocaine | 1 | 2003 | 49 | 0.060 |
Why?
| Polymerase Chain Reaction | 1 | 2004 | 453 | 0.050 |
Why?
| Anesthetics, Local | 1 | 2003 | 75 | 0.050 |
Why?
| Recombinant Fusion Proteins | 1 | 2004 | 181 | 0.050 |
Why?
| Cell Division | 1 | 2004 | 292 | 0.050 |
Why?
| Hemorrhage | 1 | 2004 | 197 | 0.050 |
Why?
| Recombinant Proteins | 1 | 2004 | 486 | 0.050 |
Why?
| Oocytes | 1 | 2003 | 74 | 0.050 |
Why?
| Acute Disease | 3 | 2008 | 366 | 0.050 |
Why?
| Hepatocytes | 2 | 2013 | 182 | 0.050 |
Why?
| Amphetamines | 1 | 2002 | 29 | 0.050 |
Why?
| Phencyclidine | 1 | 2002 | 38 | 0.050 |
Why?
| Parkinsonian Disorders | 1 | 2001 | 10 | 0.050 |
Why?
| Excitatory Amino Acid Antagonists | 1 | 2002 | 51 | 0.050 |
Why?
| Dinoprostone | 2 | 2014 | 53 | 0.050 |
Why?
| Proto-Oncogene Proteins c-fos | 1 | 2001 | 61 | 0.050 |
Why?
| Proto-Oncogene Proteins c-jun | 1 | 2001 | 75 | 0.050 |
Why?
| Dopamine Uptake Inhibitors | 1 | 2002 | 56 | 0.050 |
Why?
| Proteins | 1 | 2004 | 342 | 0.050 |
Why?
| Asthma | 1 | 2005 | 281 | 0.050 |
Why?
| Receptors, N-Methyl-D-Aspartate | 1 | 2002 | 127 | 0.050 |
Why?
| Proto-Oncogene Proteins c-akt | 2 | 2014 | 157 | 0.050 |
Why?
| Molecular Targeted Therapy | 1 | 2021 | 119 | 0.050 |
Why?
| Infusions, Intra-Arterial | 2 | 2014 | 15 | 0.050 |
Why?
| Mitomycin | 2 | 2014 | 20 | 0.050 |
Why?
| Fluorouracil | 2 | 2014 | 54 | 0.040 |
Why?
| Hepatic Artery | 2 | 2014 | 21 | 0.040 |
Why?
| Hepatitis B Surface Antigens | 2 | 2013 | 9 | 0.040 |
Why?
| Disease Management | 1 | 2021 | 174 | 0.040 |
Why?
| Protein Kinase Inhibitors | 1 | 2021 | 204 | 0.040 |
Why?
| Inflammation | 1 | 2003 | 604 | 0.040 |
Why?
| Predictive Value of Tests | 2 | 2012 | 903 | 0.040 |
Why?
| Transfection | 2 | 2013 | 354 | 0.040 |
Why?
| Lymphocytes | 1 | 2020 | 152 | 0.040 |
Why?
| Neutrophils | 1 | 2020 | 145 | 0.040 |
Why?
| Neoplasm Metastasis | 1 | 2019 | 231 | 0.040 |
Why?
| Reference Values | 2 | 2012 | 310 | 0.040 |
Why?
| Cell Movement | 3 | 2003 | 247 | 0.040 |
Why?
| Incidence | 2 | 2014 | 1003 | 0.040 |
Why?
| Calcium | 3 | 2003 | 396 | 0.040 |
Why?
| Brain | 2 | 2002 | 1328 | 0.030 |
Why?
| Amino Acid Sequence | 2 | 2010 | 585 | 0.030 |
Why?
| Probability | 2 | 2009 | 164 | 0.030 |
Why?
| Smoke | 1 | 2015 | 18 | 0.030 |
Why?
| Fluorescent Antibody Technique | 1 | 2014 | 108 | 0.030 |
Why?
| Interferon-alpha | 1 | 2014 | 47 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2014 | 143 | 0.030 |
Why?
| Viral Load | 1 | 2014 | 76 | 0.030 |
Why?
| Drug Resistance, Viral | 1 | 2013 | 8 | 0.030 |
Why?
| Hepatitis B e Antigens | 1 | 2013 | 4 | 0.030 |
Why?
| Appendectomy | 1 | 2014 | 33 | 0.030 |
Why?
| Transcriptional Activation | 1 | 2014 | 121 | 0.030 |
Why?
| Early Detection of Cancer | 1 | 2015 | 169 | 0.030 |
Why?
| Depression, Chemical | 2 | 2003 | 13 | 0.030 |
Why?
| Pelvis | 1 | 2014 | 68 | 0.030 |
Why?
| PPAR gamma | 1 | 2014 | 73 | 0.030 |
Why?
| Adenoviridae | 1 | 2013 | 51 | 0.030 |
Why?
| Abdomen | 1 | 2014 | 76 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 181 | 0.030 |
Why?
| Proportional Hazards Models | 2 | 2004 | 402 | 0.030 |
Why?
| Immunophenotyping | 1 | 2013 | 109 | 0.030 |
Why?
| Promoter Regions, Genetic | 2 | 2006 | 475 | 0.030 |
Why?
| Neoplastic Stem Cells | 1 | 2014 | 103 | 0.030 |
Why?
| Antineoplastic Agents | 1 | 2021 | 1171 | 0.030 |
Why?
| Genetic Vectors | 1 | 2013 | 125 | 0.030 |
Why?
| Genome, Viral | 1 | 2013 | 79 | 0.030 |
Why?
| Tomography, X-Ray Computed | 2 | 2009 | 1159 | 0.030 |
Why?
| Dependovirus | 1 | 2013 | 101 | 0.030 |
Why?
| Albuterol | 2 | 2003 | 54 | 0.030 |
Why?
| Elasticity | 1 | 2012 | 20 | 0.030 |
Why?
| Blotting, Western | 1 | 2014 | 601 | 0.030 |
Why?
| Platelet Count | 1 | 2012 | 72 | 0.030 |
Why?
| Ubiquitination | 1 | 2012 | 43 | 0.030 |
Why?
| Alanine Transaminase | 1 | 2012 | 124 | 0.030 |
Why?
| Liver Function Tests | 1 | 2012 | 47 | 0.030 |
Why?
| RNA, Small Interfering | 1 | 2012 | 215 | 0.020 |
Why?
| Dopamine | 2 | 2003 | 171 | 0.020 |
Why?
| Base Sequence | 1 | 2012 | 643 | 0.020 |
Why?
| Drug Resistance, Bacterial | 1 | 2011 | 71 | 0.020 |
Why?
| Cerebral Cortex | 2 | 2002 | 200 | 0.020 |
Why?
| Blotting, Southern | 1 | 2010 | 42 | 0.020 |
Why?
| Blotting, Northern | 1 | 2010 | 109 | 0.020 |
Why?
| Sequence Deletion | 1 | 2010 | 66 | 0.020 |
Why?
| Hyperamylasemia | 1 | 2008 | 1 | 0.020 |
Why?
| Fatty Alcohols | 1 | 2008 | 2 | 0.020 |
Why?
| Mice, Inbred ICR | 1 | 2008 | 22 | 0.020 |
Why?
| I-kappa B Proteins | 1 | 2008 | 16 | 0.020 |
Why?
| Metabolic Clearance Rate | 1 | 2009 | 68 | 0.020 |
Why?
| Radionuclide Imaging | 1 | 2009 | 116 | 0.020 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 83 | 0.020 |
Why?
| Statistics, Nonparametric | 1 | 2009 | 194 | 0.020 |
Why?
| Liver Regeneration | 1 | 2008 | 49 | 0.020 |
Why?
| Hyperplasia | 1 | 2008 | 96 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2009 | 206 | 0.020 |
Why?
| Bacterial Infections | 1 | 2009 | 95 | 0.020 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 141 | 0.020 |
Why?
| Cell Nucleus | 1 | 2008 | 183 | 0.020 |
Why?
| Mucous Membrane | 1 | 2007 | 28 | 0.020 |
Why?
| Duodenum | 1 | 2007 | 35 | 0.020 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2008 | 197 | 0.020 |
Why?
| Nitric Oxide | 1 | 2009 | 253 | 0.020 |
Why?
| Esophagus | 1 | 2007 | 84 | 0.020 |
Why?
| Flavones | 1 | 2006 | 5 | 0.020 |
Why?
| Dactinomycin | 1 | 2006 | 22 | 0.020 |
Why?
| Receptors, Aryl Hydrocarbon | 1 | 2006 | 25 | 0.020 |
Why?
| S100 Proteins | 1 | 2006 | 34 | 0.020 |
Why?
| RNA Processing, Post-Transcriptional | 1 | 2006 | 24 | 0.020 |
Why?
| Treatment Failure | 1 | 2006 | 114 | 0.020 |
Why?
| DNA, Complementary | 1 | 2006 | 135 | 0.020 |
Why?
| Emergencies | 1 | 2006 | 86 | 0.020 |
Why?
| Chemokine CCL17 | 1 | 2005 | 1 | 0.020 |
Why?
| Chemokine CCL22 | 1 | 2005 | 2 | 0.020 |
Why?
| Skin | 1 | 2008 | 409 | 0.020 |
Why?
| Peak Expiratory Flow Rate | 1 | 2005 | 9 | 0.020 |
Why?
| Th2 Cells | 1 | 2005 | 21 | 0.020 |
Why?
| Sulfides | 1 | 2005 | 28 | 0.020 |
Why?
| Cyclopropanes | 1 | 2005 | 23 | 0.020 |
Why?
| Acids | 1 | 2005 | 11 | 0.020 |
Why?
| Stress, Psychological | 1 | 2007 | 260 | 0.020 |
Why?
| Respiratory Function Tests | 1 | 2005 | 90 | 0.020 |
Why?
| Drug Resistance | 1 | 2005 | 63 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2008 | 1037 | 0.020 |
Why?
| Hydrogen-Ion Concentration | 1 | 2005 | 175 | 0.020 |
Why?
| alpha-Fetoproteins | 1 | 2004 | 15 | 0.020 |
Why?
| Hemostasis, Surgical | 1 | 2004 | 12 | 0.020 |
Why?
| RNA | 1 | 2006 | 170 | 0.020 |
Why?
| Leucovorin | 1 | 2004 | 20 | 0.020 |
Why?
| Hepatitis C Antibodies | 1 | 2004 | 20 | 0.020 |
Why?
| Hepatectomy | 1 | 2004 | 22 | 0.020 |
Why?
| Transcription Factors | 1 | 2008 | 561 | 0.020 |
Why?
| Endoscopes, Gastrointestinal | 1 | 2004 | 3 | 0.010 |
Why?
| Virulence Factors | 1 | 2005 | 78 | 0.010 |
Why?
| Omeprazole | 1 | 2004 | 17 | 0.010 |
Why?
| Cardiolipins | 1 | 2004 | 1 | 0.010 |
Why?
| Dizziness | 1 | 2004 | 13 | 0.010 |
Why?
| Hydronephrosis | 1 | 2004 | 12 | 0.010 |
Why?
| Pancreatitis, Alcoholic | 1 | 2003 | 2 | 0.010 |
Why?
| Exanthema | 1 | 2004 | 32 | 0.010 |
Why?
| Ribosomal Proteins | 1 | 2004 | 25 | 0.010 |
Why?
| Chemokine CCL4 | 1 | 2003 | 5 | 0.010 |
Why?
| Chemokine CCL3 | 1 | 2003 | 8 | 0.010 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 102 | 0.010 |
Why?
| Double-Blind Method | 1 | 2005 | 681 | 0.010 |
Why?
| Autoantibodies | 1 | 2004 | 116 | 0.010 |
Why?
| Survival Analysis | 1 | 2004 | 653 | 0.010 |
Why?
| Dopamine Antagonists | 1 | 2002 | 20 | 0.010 |
Why?
| L-Lactate Dehydrogenase | 1 | 2002 | 65 | 0.010 |
Why?
| Binding, Competitive | 1 | 2002 | 94 | 0.010 |
Why?
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2001 | 5 | 0.010 |
Why?
| Tyrosine 3-Monooxygenase | 1 | 2001 | 11 | 0.010 |
Why?
| Neostriatum | 1 | 2001 | 10 | 0.010 |
Why?
| Glycine | 1 | 2002 | 75 | 0.010 |
Why?
| Cell Death | 1 | 2002 | 181 | 0.010 |
Why?
| Cell Membrane | 1 | 2002 | 248 | 0.010 |
Why?
| Cerebellum | 1 | 2001 | 135 | 0.010 |
Why?
| Kinetics | 1 | 2002 | 623 | 0.010 |
Why?
| Postoperative Complications | 1 | 2004 | 984 | 0.010 |
Why?
| Child | 1 | 2005 | 6847 | 0.010 |
Why?
|
|
Hsu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|